BioSante's (Nasdaq: BPAX) LibiGel Could be the Next Viagra BiotechStockTrader.com
Nasdaq: BPAX), a biotech collection focused on female sexual health, operating in the twin production as companies comparable Abbott Laboratories, Inc. NYSE: ABT) and Watson Pharmaceuticals, Inc. NYSE: WPI), could clock momentous price from its bob Episode III candidate, LibiGel, whether approved by the FDA for the treatment of FSD. LibiGel Addresses a Considerable Fling BioSante Pharmaceuticals" (Nasdaq: BPAX) wholly-owned LibiGel is a gel formulation of testosterone that is currently in Leaf III clinical trials for the treatment of Female Sexual Dysfunction (FSD).
And, according to a announce published in the Diary of the American Medical Association, around 43% of American women are estimated to combat some measure of impaired sexual function, creating an huge latent market. Nowadays in the U.S., FDA approved pharmaceutical product for this message however the act that men enjoy had Viagra for over 12 years.
Industry Fundamentals Mark In relation to M&A The pharmaceutical industry is further rapidly progressing towards a essential shift as several blockbuster drugs alteration off of patent protection. With an hugely comprehensive addressable market, a Folio III narcotic with fine probation results, and no competition much in clinical trials, BioSante"s LibiGel could be a prime rationale for a figure of companies.
For instance, Pfizer, which recently acquired Wyeth to bolster its women"s products portfolio, may hold an activity in a cramped association cognate BioSante.
Near-Term Catalysts May Guide the Inventory BioSante is looking to companion over the ensuing six to twelve months, which could completion in milestone payments and eventually royalties. In that the drug is already in Chapter III trials, the partnership should extremely be eligible for higher royalty rates that could distance between 25% and 30%. And of course, a buyout by a larger pharmaceutical business looking to bolster its pipeline is always a possibility.
The gathering is too relatively low-risk for an emerging biotech society with a healthy balance folio and $46 million in cash that should persist exceeding than a year.
Comments to this post not accepted.
